Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics, Hyperfractionated Radiotherapy, and Adebrelimab in LS-SCLC
NCT06943235Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial in small cell lung cancer (SCLC) (2 arms), sponsored by Fudan University. Primary endpoints: One year progression free survival rate at 1 year and Complete response rate at the end of radiotherapy for one month. Started Apr 2025; status: recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06943235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943235.